Oral Session 1-7A Malignant Lymphoma: Clinical Trials

[OS1-7A-3] Phase Ib/II study of copanlisib in Japanese patients with relapsed/refractory indolent B-cell NHL

Dai Maruyama¹, Noriko Fukuhara², Koji Izutsu^1,3, Toshiki Uchida⁴, Shigeru Kusumoto⁵, Junya Kuroda⁶, Chisako Iriyama⁷, Masamitsu Yanada⁷, Norifumi Tsukamoto⁸, Yoko Suehiro⁹, Hironobu Minami¹⁰, Hirokazu Nagai¹¹, Shigeo Masuda¹², Kensei Tobinai¹ (1.Hematology, National Cancer Center Hospital, Tokyo, Japan, 2.Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan, 3.Hematology, Toranomon Hospital, Tokyo, Japan, 4.Hematology Oncology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan, 5.Hematology Oncology, Nagoya City University Hospital, Nagoya, Japan, 6.Hematology Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan, 7.Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan, 8.Medicine and Clinical Science, Gunma University Hospital, Gunma, Japan, 9.Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, 10.Medical Oncology Hematology, Kobe University Hospital, Kobe, Japan, 11.Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan, 12.Bayer Yakuhin, Ltd., Osaka, Japan)